Tyresö, Sweden

Joachim Feldwisch

USPTO Granted Patents = 15 

 

Average Co-Inventor Count = 5.3

ph-index = 3

Forward Citations = 30(Granted Patents)


Location History:

  • Tyreso, SE (2017 - 2023)
  • Tyresö, SE (2013 - 2024)

Company Filing History:


Years Active: 2013-2025

Loading Chart...
Loading Chart...
15 patents (USPTO):Explore Patents

Title: Inventor Spotlight: Joachim Feldwisch from Tyresö, Sweden

Introduction

Joachim Feldwisch is a prominent inventor based in Tyresö, Sweden, renowned for his significant contributions to the field of biomedical innovations. With an impressive portfolio of 15 patents, Feldwisch is recognized for his pioneering work in engineered polypeptides, which have crucial applications in treating various interleukin-related conditions.

Latest Patents

Feldwisch's latest patents showcase his expertise in therapeutic innovations. One notable patent is for "Methods of Treatment of IL-17A Associated Conditions," which introduces a class of engineered polypeptides that exhibit a binding affinity for interleukin-17A (IL-17A). This patent highlights the use of an IL-17A binding polypeptide, characterized by the sequence EXDXAXXEIXXLPNL XXXQXXAFIXXLXX, as a diagnostic, prognostic, and therapeutic agent. Another significant patent from Feldwisch is focused on the "IL-1R-I Binding Polypeptide," detailing engineered polypeptides that bind to interleukin-1 receptor type-I (IL-1R-I) with the binding motif EXXXXXXEIXXLPNLXRXQYXAFIXXLXD. This innovation is also intended for therapeutic, prognostic, and diagnostic uses.

Career Highlights

Throughout his career, Feldwisch has collaborated with notable companies in the biotechnology sector, including Affibody AB and Swedish Orphan Biovitrum AB (publ). His work in these companies has facilitated the development of groundbreaking therapies that address significant health challenges.

Collaborations

Feldwisch has collaborated with distinguished colleagues, including Elin Gunneriusson and Nina Herne. Their collective efforts have been instrumental in advancing the understanding and treatment of conditions associated with interleukins, demonstrating the power of teamwork in the field of medical innovations.

Conclusion

Joachim Feldwisch exemplifies the spirit of innovation and dedication in the biotechnology landscape. His extensive patent portfolio and collaborations reflect his commitment to developing effective therapeutic solutions. As advancements in biomedical research continue, Feldwisch’s contributions will undoubtedly play a vital role in transforming treatment options for IL-17A and IL-1R-related conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…